|
- HAEGARDA® Helps Prevent Hereditary Angioedema (HAE) Attacks
HAEGARDA ®, C1 Esterase Inhibitor Subcutaneous (Human), is an injectable medicine used to prevent swelling and or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE)
- HAEGARDA | C1 Esterase Inhibitor Subcutaneous (Human)
HAEGARDA ®, C1 Esterase Inhibitor Subcutaneous (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older
- See Full Prescribing Information | HAEGARDA®
HAEGARDA ®, C1 Esterase Inhibitor Subcutaneous (Human), is an injectable medicine used to prevent swelling and or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE)
- How HAEGARDA Helps Treat HAE Attacks | HAEGARDA®
HAEGARDA ®, C1 Esterase Inhibitor Subcutaneous (Human), is an injectable medicine used to prevent swelling and or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE)
- Starting a HAEGARDA CSL Prescription | HAEGARDA®
HAEGARDA ®, C1 Esterase Inhibitor Subcutaneous (Human), is an injectable medicine used to prevent swelling and or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE)
- HAEGARDA | The HEGARDA Difference
HAEGARDA is an injectable medicine used to prevent swelling and or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE)
- HAEGARDA | Individualized Dosing
HAEGARDA ®, C1 Esterase Inhibitor Subcutaneous (Human), is a plasma-derived concentrate of C1 Esterase Inhibitor (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older
- FAQs - HAEGARDA
HAEGARDA, the only subcutaneous injectable C1-INH for the prevention of HAE attacks, is approved for use in adults and patients 6 years of age and older You should not use HAEGARDA if you have experienced life-threatening immediate hypersensitivity reactions, including anaphylaxis, to HAEGARDA
|
|
|